Article
Oral live attenuated human rotavirus vaccine (Rotarix™) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian children.
Memorias do Instituto Oswaldo Cruz - 1 Nov 2012
Justino Maria Cleonice A, Araújo Eliete C, van Doorn Leen-Jan, Oliveira Consuelo S, Gabbay Yvone B, Mascarenhas Joana D'Arc P, Miranda Yllen S, Guerra Sylvia de Fátima S, Silva Veronilce B da, Linhares Alexandre C
Abstract excerpt
In a large Phase III trial conducted in 10 Latin American countries, the safety and efficacy of the live attenuated monovalent rotavirus vaccine RIX4414 was evaluated in 15,183 healthy infants followed up during the first two years of life. Belém was the only site in Brazil included in this multicentre trial. The study in Belém included a subset of 653 infants who were followed up until 24 months of age for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.